Dilpacimab (ABT165) is a bispecific variable domain immunoglobulin. Dilpacimab binds to and inhibits DLL4 and VEGF and acts as a tumor growth inhibitor. Dilpacimab can be used in research related to metastatic colorectal cancer and advanced solid tumors [1] [2].
In Vivo, When combined with chemotherapeutic agents in preclinical xenograft models, Dilpacimab not only induces a stronger anti-tumor response but also achieves superior efficacy compared to anti-VEGF monotherapy[2].
References:
[1]. Strickler JH, et al. Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study. Future Oncol. 2022;18(27):3011-3020.
[2]. Gordon MS, et al. Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2021;20(10):1988-1995.
In Vivo, When combined with chemotherapeutic agents in preclinical xenograft models, Dilpacimab not only induces a stronger anti-tumor response but also achieves superior efficacy compared to anti-VEGF monotherapy[2].
References:
[1]. Strickler JH, et al. Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study. Future Oncol. 2022;18(27):3011-3020.
[2]. Gordon MS, et al. Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2021;20(10):1988-1995.